<DOC>
	<DOC>NCT03087162</DOC>
	<brief_summary>New drug regimen for Helicobacter pylori eradication, the investigators compare once daily dose dexlansoprazole levofloxacin based quadruple therapy and twice daily dose dexlansoprazole levofloxacin quadruple therapy for helicobacter pylori eradication.</brief_summary>
	<brief_title>Once Daily Dose Dexlansoprazole Quadruple Therapy for Helicobacter Pylori</brief_title>
	<detailed_description>Once daily dose dexlansoprazole should be non inferior to twice daily dose in the eradication of Helicobacter pylori infection.</detailed_description>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>1. Age 1875 yearpatient 2. Diagnosed as positive Helicobacter Pylori testing by any of the following methods: Rapid urease test or Histology 3. Inform consent 1. Previous history of Helicobacter pylori eradication 2. Contraindications or allergic reactions to the study drugs 3. Previous gastric surgery or advanced gastric cancer or other malignancy or other severe concurrent diseases 4. Decompensated Liver cirrhosis or chronic kidney disease (GFR&lt; 30) 5. Mental disorders or alcohol or drug addiction 6. Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>